StockData
Propanc Biopharma, Inc. logo

Propanc Biopharma, Inc. (PPCB) stock

PPCBNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 2/30
$1.76−0.12 (-6.38%)

Close on Nov 18, 2026Market cap $1.73MP/E –Yield –

Propanc Biopharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Propanc Biopharma's free cash flow for the twelve months ending Jun 30, 2026 was -$5.69M. For fiscal 2026 it was -$5.69M. The highest annual figure on record is -$226.44K in fiscal 2014.

Annual free cash flow

PeriodPeriod endValueChange
FY2026Jun 30, 2026-$5.69M–
FY2019Jun 30, 2019-$2.06M–
FY2016Jun 30, 2016-$4.51M–
FY2015Jun 30, 2015-$1.43M–
FY2014Jun 30, 2014-$226.44K–
FY2011Jun 30, 2011-$1.40M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jun 30, 2026-$1.60M–
Q3 FY2026CQ1 2026Mar 31, 2026-$1.14M–
Q2 FY2026CQ4 2025Dec 31, 2025-$1.00M–
Q1 FY2026CQ3 2025Sep 30, 2025-$1.94M–
Q4 FY2019CQ2 2019Jun 30, 2019-$266.23K–
Q3 FY2019CQ1 2019Mar 31, 2019-$738.23K–
Q2 FY2017CQ4 2016Dec 31, 2016-$321.03K–

More Propanc Biopharma figures

See a number that looks wrong?